https://wiki.esmrmb.org/api.php?action=feedcontributions&feedformat=atom&user=LarsEOlsson 2026-10-18T20:44:01Z User contributions MediaWiki 1.42.1 https://wiki.esmrmb.org/index.php?title=Magnetic_Resonance_Imaging_Biomarkers_for_early_treatment_response_in_radiotherapy&diff=828 2025-03-24T11:08:14Z

<p>LarsEOlsson: </p> <hr /> <div>{{Member Session<br /> | title= Magnetic Resonance Imaging Biomarkers for assessment of early treatment response in radiotherapy<br /> | short_text= Cancer is to a large extent treated with radiotherapy, which is delivered to the patients in several fractions. The treatment can extend over several weeks. There is a great need for imaging methods, especially MRI, that can assess the treatment response during the treatment. With the right knowledge of the response in the tumour, the treatment can be adapted. The radiation dose can be increased if the response is low, or the dose can be reduced if the response is high. In the latter case a reduction of the dose can result in less side effects. MRI as an imaging technique has the advantage of providing functional read-outs (DWI, DCE, DSC etc) and thereby be more sensitive to changes in the tumour, than otherwise is possible. In many oncology centers there is a dedicated MR-scanner that can provide these measurements at different occasions during the treatment. The new modality MR-linac, which is a combination of a treatment machine and MR-scanner, further provides the possibility to make day-to-day adaptations. In this session the new concept of using MR imaging biomarkers for radiotherapy is explained, applications are described and future possibilities discussed.<br /> | duration= 60m<br /> | audience= Physicists, Radiologists, Oncologists<br /> | Moderators= Lars E. Olsson, Petra van Houdt<br /> | Moderators_Confirmed= Lars E. Olsson, Petra van Houdt<br /> | Speaker1= Faisal Mahmood<br /> | Speaker2= Tord Hompland<br /> | Speaker1_Confirmed= Faisal Mahmood<br /> | Speaker2_Confirmed= Tord Hompland<br /> }}<br /> <br /> &lt;!-- Add the full description of the session here below --&gt;<br /> <br /> == Session description ==<br /> <br /> This session will be about...<br /> <br /> The program will be the following:<br /> <br /> * Introduction ''(10 min)''<br /> * Presentation by Paul Lauterbur ''(15 min)''<br /> * Presentation by Peter Mansfield ''(15 min)''<br /> * Questions and Answers ''(20 min)''</div>

LarsEOlsson https://wiki.esmrmb.org/index.php?title=Magnetic_Resonance_Imaging_Biomarkers_for_early_treatment_response_in_radiotherapy&diff=827 2025-03-24T11:07:05Z

<p>LarsEOlsson: </p> <hr /> <div>{{Member Session<br /> | title= Magnetic Resonance Imaging Biomarkers for assessment of early treatment response in radiotherapy<br /> | short_text= Cancer is to a large extent treated with radiotherapy, which is delivered to the patients in several fractions. The treatment can extend over several weeks. There is a great need for imaging methods, especially MRI, that can assess the treatment response during the treatment. With the right knowledge of the response in the tumour, the treatment can be adapted. The radiation dose can be increased if the response is low, or the dose can be reduced if the response is high. In the latter case a reduction of the dose can result in less side effects. MRI as an imaging technique has the advantage of providing functional read-outs (DWI, DCE, DSC etc) and thereby be more sensitive to changes in the tumour, than otherwise is possible. In many oncology centers there is a dedicated MR-scanner that can provide these measurements at different occasions during the treatment. The new modality MR-linac, which is a combination of a treatment machine and MR-scanner, further provides the possibility to make day-to-day adaptations. In this session the new concept of using MR imaging biomarkers for radiotherapy is explained, applications are described and future possibilities discussed.<br /> | duration= 60m<br /> | audience= Physicists, Radiologists, Oncologists<br /> | Moderators= Lars E. Olsson, Petra van Houdt<br /> | Moderators_Confirmed= Lars E. Olsson, Petra van Houdt<br /> | Speaker1= Faisal Mahmood<br /> | Speaker1_Confirmed= Faisal Mahmood<br /> | Speaker2_Confirmed= Tord Hompland<br /> }}<br /> <br /> &lt;!-- Add the full description of the session here below --&gt;<br /> <br /> == Session description ==<br /> <br /> This session will be about...<br /> <br /> The program will be the following:<br /> <br /> * Introduction ''(10 min)''<br /> * Presentation by Paul Lauterbur ''(15 min)''<br /> * Presentation by Peter Mansfield ''(15 min)''<br /> * Questions and Answers ''(20 min)''</div>

LarsEOlsson https://wiki.esmrmb.org/index.php?title=Magnetic_Resonance_Imaging_Biomarkers_for_early_treatment_response_in_radiotherapy&diff=745 2025-02-14T09:32:59Z

<p>LarsEOlsson: Magnetic Resonance Imaging Biomarkers for early treatment response in radiotherapy</p> <hr /> <div>{{Member Session<br /> | title= Magnetic Resonance Imaging Biomarkers for assessment of early treatment response in radiotherapy<br /> | short_text= Cancer is to a large extent treated with radiotherapy, which is delivered to the patients in several fractions. The treatment can extend over several weeks. There is a great need for imaging methods, especially MRI, that can assess the treatment response during the treatment. With the right knowledge of the response in the tumour, the treatment can be adapted. The radiation dose can be increased if the response is low, or the dose can be reduced if the response is high. In the latter case a reduction of the dose can result in less side effects. MRI as an imaging technique has the advantage of providing functional read-outs (DWI, DCE, DSC etc) and thereby be more sensitive to changes in the tumour, than otherwise is possible. In many oncology centers there is a dedicated MR-scanner that can provide these measurements at different occasions during the treatment. The new modality MR-linac, which is a combination of a treatment machine and MR-scanner, further provides the possibility to make day-to-day adaptations. In this session the new concept of using MR imaging biomarkers for radiotherapy is explained, applications are described and future possibilities discussed.<br /> | duration= 60m<br /> | audience= Physicists, Radiologists, Oncologists<br /> | Moderators= Lars E. Olsson, Petra van Houdt<br /> | Moderators_Confirmed= Lars E. Olsson, Petra van Houdt<br /> | Speaker1= Faisal Mahmood<br /> | Speaker1_Confirmed= Faisal Mahmood<br /> | Speaker2= Tord Hompland<br /> }}<br /> <br /> &lt;!-- Add the full description of the session here below --&gt;<br /> <br /> == Session description ==<br /> <br /> This session will be about...<br /> <br /> The program will be the following:<br /> <br /> * Introduction ''(10 min)''<br /> * Presentation by Paul Lauterbur ''(15 min)''<br /> * Presentation by Peter Mansfield ''(15 min)''<br /> * Questions and Answers ''(20 min)''</div>

LarsEOlsson